Phase 3 MagnetisMM-32
Elranatamab (bispecific) alone versus three standard combinations.
For whom: Relapsed patients after anti-CD38 and lenalidomide
In Portugal: Lisbon, Braga
ClinicalTrials.gov · NCT06152575 ↗
mielomamultiplo.com · Multiple Myeloma
Recent developments regarding the treatment and research of multiple myeloma indicate promising advances. [USA] A new bispecific antibody targeting BCMA is being tested in patients with relapsed multiple myeloma, while [UK] the inhibition of the NFIL3-MYC axis is emerging as a strategy to overcome therapeutic resistance. [Unidentified Country] New therapies, including CAR-T therapies and antibody combinations, are being approved, and FDA data analysis suggests the potential of Teclistamab with Daratumumab.
Made by MielomaAI On November 17, 2026, at 09:45, based on recent news. May contain errors. View news →
A clinical trial is a study in which a new treatment is compared with the best treatment that already exists. This is how new medicines arrive — and it can give access to them before approval. Taking part is voluntary, at no cost to the patient, and you can withdraw at any time. Ask your haematologist whether there is a trial suitable for your case.
Multiple myeloma trials with centers in Portugal marked as "recruiting" on ClinicalTrials.gov (updated November 17, 2026). The trial team, in consultation with the patient's hematologist, decides whether a patient can participate.
Phase 3 MagnetisMM-32
Elranatamab (bispecific) alone versus three standard combinations.
For whom: Relapsed patients after anti-CD38 and lenalidomide
In Portugal: Lisbon, Braga
ClinicalTrials.gov · NCT06152575 ↗Phase 3 MajesTEC-7
Teclistamab or talquetamab (bispecifics) with daratumumab and lenalidomide, versus the standard treatment.
For whom: Newly diagnosed
In Portugal: Braga, Lisbon, Porto
ClinicalTrials.gov · NCT05552222 ↗Phase 1/2 Surzetoclax
Surzetoclax, a new tablet, alone or with other myeloma medicines. It studies safety and effect.
For whom: Myeloma patients (various stages)
In Portugal: Lisbon, Braga, Porto
ClinicalTrials.gov · NCT06953960 ↗Phase 3 TRIlogy-7
Ramantamig, a new Janssen medicine, with daratumumab, versus the standard treatments D-VRd or D-Rd.
For whom: Newly diagnosed with no transplant planned
In Portugal: Braga, Lisbon, Porto, Vila Real
ClinicalTrials.gov · NCT07665450 ↗Phase 3 Linvoseltamab (EMN)
Linvoseltamab (bispecific) versus the standard treatment with daratumumab, lenalidomide and dexamethasone.
For whom: Newly diagnosed who cannot have a transplant
In Portugal: Coimbra, Lisbon
ClinicalTrials.gov · NCT06932562 ↗Phase 2 TRI Pro
Whether giving tocilizumab before ramantamig prevents cytokine release syndrome (an inflammatory reaction).
For whom: Relapsed patients
In Portugal: Braga, Lisbon, Porto, Vila Nova de Gaia
ClinicalTrials.gov · NCT07589634 ↗Phase 3 SUCCESSOR-1
Mezigdomide (CELMoD) with bortezomib and dexamethasone, versus pomalidomide, bortezomib and dexamethasone.
For whom: Relapsed patients
In Portugal: Braga, Lisbon, Porto
ClinicalTrials.gov · NCT05519085 ↗Phase 3 QUINTESSENTIAL-2
BMS-986393, a new CAR-T, versus the standard treatments.
For whom: Relapsed patients who have already had lenalidomide
In Portugal: Porto
ClinicalTrials.gov · NCT06615479 ↗Sample study EMN36
A European Myeloma Network project that stores biological samples for research. It does not test medicines.
For whom: Myeloma patients
In Portugal: Coimbra, Lisbon, Porto
ClinicalTrials.gov · NCT06237803 ↗Phase 3 Completed · changed practice
What it tested: Adding daratumumab to VRd (bortezomib, lenalidomide and dexamethasone), before and after transplant.
For whom: Newly diagnosed patients who can have a transplant.
PERSEUS (with transplant): progression-free at 4 years
PERSEUS: severe effects (grade 3 or 4), with and without daratumumab
any grade severe (grade 3 or higher)
Phase 3 Completed (final analysis in 2026)
What it tested: Adding daratumumab to VRd in people who do not have a transplant or postpone it.
For whom: Newly diagnosed patients with no transplant planned.
Patients without transplant treated with D-VRd
D-VRd in CEPHEUS (with bortezomib and lenalidomide)
Neuropathy is mainly linked to bortezomib; giving bortezomib under the skin and once a week helps reduce it.
Source: CancerNetwork ↗any grade severe (grade 3 or higher)
D-VRd reduced the risk of progression or death by 43% compared with VRd.
Source: Pharmacy Times ↗Phase 3 Completed · changed practice
What it tested: Adding isatuximab to VRd.
For whom: Newly diagnosed patients who cannot have a transplant.
IMROZ (without transplant): progression-free at 5 years
Phase 3 Completed
What it tested: Having the transplant straight away, or keeping it for later, after VRd.
For whom: Newly diagnosed patients who can have a transplant.
DETERMINATION: median progression-free time
DETERMINATION: alive at 5 years (survival was similar)
Phase 3 Completed · in follow-up
What it tested: A single infusion of cilta-cel (CAR-T) versus the standard treatments.
For whom: Relapsed patients, from the 2nd line, resistant to lenalidomide.
CARTITUDE-4 (cilta-cel, from the 2nd line): median progression-free time
CARTITUDE-4 (cilta-cel, from the 2nd line): patients after two and a half years
Cilta-cel in CARTITUDE-4 (176 patients)
CARTITUDE-4: severe effects, cilta-cel versus standard treatment
any grade severe (grade 3 or higher)
Phase 1b/2 Completed · long follow-up
What it tested: Cilta-cel (CAR-T) in patients who had already had many treatments.
For whom: Patients with, on average, 6 previous treatments.
CARTITUDE-1 (cilta-cel, patients with many previous treatments): medians
CARTITUDE-1: patients without progression and without any other treatment 5 years or more after a single infusion
Phase 3 Completed
What it tested: Ide-cel (Abecma, CAR-T) versus standard treatments.
For whom: Relapsed patients after 2 to 4 treatments.
Ide-cel (Abecma) versus standard treatments: average time without worsening
Patients who responded
Phase 2 FDA decision on 23/12/2026
What it tested: Anito-cel, a new CAR-T, in a single infusion.
For whom: Relapsed patients after 3 or more treatments.
Results in the 117 patients
Phase 1 Under study · not yet approved
What it tested: A single infusion that turns T cells inside the body into CAR-T against BCMA: no cell collection, no factory and no conditioning chemotherapy.
For whom: Relapsed patients after several treatments (Australia, USA and China). There are no trials in Portugal yet.
First results (few patients, short follow-up)
In the ESO-T01 trial one patient with a lesion outside the bone marrow (spinal cord compression) died. The authors call for more care in selecting patients with this type of lesion.
Source: Fierce Biotech ↗Phase 3 Completed · approved in Europe (2026)
What it tested: Teclistamab (bispecific) with daratumumab.
For whom: Relapsed patients, from the 2nd line.
MajesTEC-3 (teclistamab + daratumumab): alive at 3 years
Phase 3 Main results in October 2026
What it tested: Elranatamab alone versus three standard combinations.
For whom: Relapsed patients after anti-CD38 and lenalidomide.
Elranatamab: initial results
Median progression-free time has not yet been reached. There is a trial recruiting in Lisbon and Braga.
Source: Targeted Oncology ↗Phase 3 Completed · approved
What it tested: Belantamab with bortezomib and dexamethasone (BVd) versus daratumumab with bortezomib and dexamethasone.
For whom: Relapsed patients, from the 2nd line.
DREAMM-7 (BVd versus DVd)
Belantamab in DREAMM-7: eye effects
In most cases they improve when the dose is delayed or reduced. Regular eye appointments are needed.
Source: NEJM (DREAMM-7) / CancerNetwork ↗any grade severe (grade 3 or higher)
Phase 3 Completed · in follow-up
What it tested: Belantamab with pomalidomide and dexamethasone (BPd) versus pomalidomide, bortezomib and dexamethasone (PVd).
For whom: Relapsed patients who have already had lenalidomide.
Median progression-free time
Phase 3 Results in May 2026
What it tested: Mezigdomide (CELMoD) with carfilzomib and dexamethasone.
For whom: Relapsed patients.
SUCCESSOR-2 (mezigdomide + Kd versus Kd): median progression-free time
The sister trial, SUCCESSOR-1, is recruiting in Porto, Lisbon and Braga.
Source: IMF ↗Phase 3 Completed · approved
What it tested: Daratumumab versus monitoring only.
For whom: People with high-risk smouldering myeloma.
AQUILA (high-risk smouldering myeloma), at 5 years
How to read the numbers: “median progression-free time” is the time after which half of the patients still did not have their disease getting worse; “not yet reached” means that, when the study was published, more than half were still progression-free. These are results from selected patients and do not say what will happen to each person.
Percentage of patients in each trial who had each effect. The light bar is any grade; the dark part is severe cases (grade 3 or higher). The numbers come from selected patients and do not say what will happen to each person; many effects are prevented or treated by the team.
Cilta-cel in CARTITUDE-4 (176 patients)
CARTITUDE-4: severe effects, cilta-cel versus standard treatment
any grade severe (grade 3 or higher)
Teclistamab in MajesTEC-1 (165 patients)
Talquetamab in MonumenTAL-1: effects specific to this medicine
any grade severe (grade 3 or higher)
Belantamab in DREAMM-7: eye effects
In most cases they improve when the dose is delayed or reduced. Regular eye appointments are needed.
Source: NEJM (DREAMM-7) / CancerNetwork ↗any grade severe (grade 3 or higher)
Daratumumab: reactions during administration (COLUMBA)
PERSEUS: severe effects (grade 3 or 4), with and without daratumumab
any grade severe (grade 3 or higher)
D-VRd in CEPHEUS (with bortezomib and lenalidomide)
Neuropathy is mainly linked to bortezomib; giving bortezomib under the skin and once a week helps reduce it.
Source: CancerNetwork ↗any grade severe (grade 3 or higher)
Phase 3 trial with 523 patients relapsing after anti-CD38 and lenalidomide: it met its main goal (progression-free time). More severe infections in the elranatamab arm.
Source: IMF ↗Updated data from the phase 1 trial (ASCO and EHA 2026 congresses): evaluable patients had no detectable disease, with the CAR-T created inside the body from a single infusion.
Source: Targeted Oncology ↗With more than 6 years of follow-up, adding daratumumab to VRd gave deeper and longer-lasting responses in patients who do not have a transplant.
Source: Pharmacy Times ↗Presented at the ASCO congress: median progression-free time of 18 months with MeziKd versus 8.3 months with Kd.
Source: Targeted Oncology ↗First complete study of a CAR-T made inside the body in myeloma: the cancer was eliminated in 3 of 5 patients, but one patient died from a complication linked to a lesion outside the bone marrow.
Source: Fierce Biotech ↗Phase 2 trial with 117 heavily treated patients: 97% responded and 68% had a complete response or better, with a single infusion.
Source: Multiple Myeloma Hub ↗With longer follow-up, median progression-free time was 32.6 months with BPd versus 12.5 months with PVd, in patients who had already had lenalidomide.
Source: CancerNetwork ↗At the ASH 2025 congress: the first 4 patients had no detectable disease after 1 month, with no cell collection, no factory and no conditioning chemotherapy.
Source: OncLive ↗In patients with standard-risk cytogenetics treated with cilta-cel, 80.5% were progression-free and 87.3% alive at 30 months (ASH 2025 congress).
Source: OncLive ↗The biggest haematology congress of the year, with new data on CAR-T, bispecifics and first line.
Source: ASH ↗FDA target date for the accelerated approval of anitocabtagene autoleucel (iMMagine-1 trial).
Source: Targeted Oncology ↗With the MagnetisMM-5 and MagnetisMM-32 results, Pfizer announced it will submit the data to the agencies.
Source: Fierce Pharma ↗After SUCCESSOR-2, an approval application is expected. There is no decision date yet.
Source: IMF ↗The CARTITUDE-5 (no transplant) and CARTITUDE-6 (CAR-T instead of transplant) trials have not yet published results (October 2026). No official date.
Source: J&J Medical Connect ↗Questions about your rights in a trial? Ask MielomaAI in Where to find help (“Can I take part in a clinical trial?”). This site does not replace your doctor.

Comprehensive and up-to-date news coverage, gathered from sources around the world by Google News.

Ben Derman: Top 10 Myeloma Abstracts to Be Presented at ASH 2026 / ASCO, ASH 2026, Ben Derman, cancer, CAR-T, DARA, Daratumumab, Lenalidomide, Mount Sinai

MRD is becoming a very valuable tool, but it's not an exclusive tool, says expert
All news → · Summaries created by MielomaAI; expand the article to read the original.
The symbol brings together two stories: that of the macedotuga.com, from Vila do Conde, and that of multiple myeloma.
It is always better to be an informed patient. There is hope. There is a way forward.